Lisata Therapeutics (LSTA) SVP gets stock awards and options grant

Rhea-AI Filing Summary

Lisata Therapeutics, Inc. executive Tariq Imam, SVP Business Development and General Counsel, reported new equity awards and related tax withholdings. On January 9, 2026, he received 15,000 shares of common stock as restricted stock awards under the company’s 2018 Equity Incentive Compensation Plan at a price of $0. These restricted shares vest in four equal parts: one-quarter on the grant date and one-quarter on each of the first three anniversaries.

After this grant, he directly owned 39,579 shares of common stock, including 17,750 unvested restricted shares. Several transactions coded "F" show a total of 1,401, 840, 747 and 513 shares of common stock withheld at $1.97 per share to cover tax liabilities from restricted stock vesting, leaving 36,078 common shares directly owned. Imam was also granted a stock option for 7,000 shares at an exercise price of $1.97 per share, with one-quarter vesting immediately on January 9, 2026 and the remainder vesting in three annual installments through an expiration date of January 9, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Imam Tariq

(Last) (First) (Middle)

C/O LISATA THERAPEUTICS, INC.

110 ALLEN ROAD, 2ND FLOOR

(Street)

BASKING RIDGE NJ 07920

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LISATA THERAPEUTICS, INC. [ LSTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Bus Dev, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		A		15,000(1)	A	$0	39,579(2)	D
Common Stock	01/09/2026		F		1,401(3)	D	$1.97	38,178(2)	D
Common Stock	01/09/2026		F		840(3)	D	$1.97	37,338(2)	D
Common Stock	01/09/2026		F		747(3)	D	$1.97	36,591(2)	D
Common Stock	01/09/2026		F		513(3)	D	$1.97	36,078(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.97	01/09/2026		A		7,000		01/09/2026(4)	01/09/2036	Common Stock	7,000	$0	7,000	D

Explanation of Responses:

1. Represents 15,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.

2. Includes 17,750 unvested restricted stock.

3. Shares withheld as payment of a tax liability on vesting of restricted stock.

4. One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date.

Remarks:

	Tariq Imam	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Lisata Therapeutics (LSTA) report for Tariq Imam?

The filing reports that Tariq Imam, SVP Business Development and General Counsel of Lisata Therapeutics, Inc., received new restricted stock awards and a stock option grant on January 9, 2026, along with share withholdings to cover taxes on vesting restricted stock.

How many restricted shares did Tariq Imam receive in the latest Lisata (LSTA) Form 4?

He received 15,000 shares of common stock as restricted stock awards under Lisata’s 2018 Equity Incentive Compensation Plan at a grant price of $0 per share.

What is the vesting schedule for Tariq Imam’s Lisata restricted stock and options?

The 15,000 restricted shares vest in four equal installments: one-quarter on the grant date and one-quarter on each of the first, second, and third anniversaries. The 7,000-share stock option at $1.97 per share vests one-quarter immediately on January 9, 2026, with additional one-quarter portions vesting on each of the first three anniversaries, and expires on January 9, 2036.

How many Lisata Therapeutics (LSTA) shares does Tariq Imam own after the reported transactions?

Following the reported transactions, he directly owns 36,078 shares of common stock, which the explanation notes includes 17,750 unvested restricted shares. He also holds a stock option for 7,000 shares of common stock.

Why were some Lisata (LSTA) shares withheld in Tariq Imam’s Form 4?

Several transactions coded "F" show 1,401, 840, 747 and 513 shares of common stock withheld at a price of $1.97 per share. The footnote explains these were shares withheld as payment of a tax liability on vesting of restricted stock.

What type of stock option did Tariq Imam receive from Lisata Therapeutics (LSTA)?

He received a stock option (right to buy) for 7,000 shares of Lisata common stock at an exercise price of $1.97 per share. The option becomes exercisable in four equal installments starting on January 9, 2026 and expires on January 9, 2036.

What is Tariq Imam’s role at Lisata Therapeutics (LSTA) according to the Form 4?

According to the filing, Tariq Imam is an officer of Lisata Therapeutics, Inc., serving as SVP, Business Development and General Counsel, and is not listed as a director or 10% owner.